Hope on the horizon: first immunotherapy drug approved for cervical cancer patients in the UK

The Cancer Drugs Fund (CDF) is set to provide the first immunotherapy drug for advanced cervical cancer patients in the UK, as NICE published its final draft guidance. The availability of this new treatment option for cervical cancer patients marks a significant milestone, offering hope to those who previously had limited options beyond standard care. The current treatment standard for patients with advanced cervical cancer (persistent, recurrent or metastatic) includes chemotherapy with or without bevacizumab. New evidence shows that the monoclonal antibody drug Keytruda™ (pembrolizumab) slows disease progression and may also extend overall survival compared to those who receive standard...